Exicorilant
- Generic Name
- Exicorilant
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23F4N7O3S
- CAS Number
- 1781244-77-6
- Unique Ingredient Identifier
- GTB859B7K8
- Background
Exicorilant is under investigation in clinical trial NCT03437941 (Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With Mcrpc).
Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT03877952
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Phase 1
Completed
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT03437941
- Locations
- 🇺🇸
New York, New York, New York, United States
🇬🇧Southampton, Southampton, England, United Kingdom
🇺🇸Scottsdale, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath